Compare Cigna Corp (CI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Zoetis Inc — how do they compare? Cigna Corp trades at $301.02 (market cap $80.25B), while Zoetis Inc trades at $74.54 (market cap $31.05B). The key difference: Cigna Corp is far larger — about 2.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| CI | ZTS | |
|---|---|---|
Market Cap | $80.25B | $31.05B |
Sector | Health | Health |
52-Week High | $311.00 | $156.76 |
52-Week Low | $244.41 | $71.91 |
Enterprise Value | $103.35B | $38.35B |
Dividend Yield | 2.06% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
Zoetis (ZTS) trades at $75.39, down 0.22% with bearish technical signals and mixed sentiment. The company maintains strong fundamentals with $9.47B revenue, 28.03% net margin, and robust profitability metrics (ROE 67.75%, ROA 18.27%). Recent Q1 2026 earnings missed expectations, while multiple law firms have filed class action lawsuits alleging securities violations between January 2025 and May 2026.
Despite strong financials and analyst consensus price target of $101.43 (34.5% upside), ZTS faces significant legal risks and technical weakness. The stock presents a value opportunity for long-term investors willing to navigate near-term volatility, though the class action lawsuits create substantial uncertainty for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
